MATTERHORN: NCT04592913: Phase 3: Neoadjuvant FLOT +/- Durvalumab Followed by Adjuvant FLOT +/- Durvalumab in GC/GEJC
NCT04592913: Phase 3: (MATTERHORN): Neoadjuvant FLOT +/- Durvalumab Followed by Adjuvant FLOT +/- Durvalumab in GC/GEJC ClinicalTrials.gov ID: NCT04592913 — MATTERHORN Official Title: A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) https://clinicaltrials.gov/study/NCT04592913 Primary Pub
Oct 4